News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
109last 24h
3129last 7d
511● bullish (7d)
313● bearish (7d)
227publishers
StockStory176d agoneutral
Therapeutics Stocks Q1 Recap: Benchmarking Halozyme Therapeutics (NASDAQ:HALO)StockStory177d agoneutral
HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 OutlookInsider Monkey180d agoneutral
Halozyme Therapeutics (HALO) Announces Global Collaboration and License Agreement With GSKMT Newswires180d agobullish
Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan StanleyGuruFocus.com180d agoneutral
Halozyme Therapeutics Inc (HALO) Q1 2026 Earnings Call Highlights: Record Revenue Growth and ...Insider Monkey181d agoneutral
H.C. Wainwright Bullish on Halozyme Therapeutics, Inc. (HALO) Commercial Revenue OutlookSimply Wall St.183d agoneutral
A Look At Halozyme Therapeutics (HALO) Valuation After Recent Share Price SwingsMarketBeat187d agoneutral
Halozyme Therapeutics AGM: Shareholders Elect Directors as CEO Torley Raises 2026 GuidanceSimply Wall St.190d agoneutral
How Investors Are Reacting To Halozyme Therapeutics (HALO) Hiring Big-Pharma Veteran Darren Snellgrove As CFOSimply Wall St.190d agobullish
How The Halozyme (HALO) Story Is Shifting Around Royalties Partnerships And Execution RiskSimply Wall St.201d agoneutral
Is Halozyme Therapeutics (HALO) Offering Value After Mixed Multi Year Share Price PerformanceStockStory201d agoneutral
1 of Wall Street’s Favorite Stock with Exciting Potential and 2 That UnderwhelmInsider Monkey203d agobullish
Is Halozyme Therapeutics (HALO) One of the Most Undervalued Biotech Stocks to Buy Right Now?